1 Supplementary Figure 1. Identification of tumorous sphere-forming CSCs and CAF feeder cells. The LEAP (Laser-Enabled Analysis and Processing) platform with laser manipulation to efficiently purify lung CSCs colonies from the co-cultured CAFs. (I) Imaging of wells, setting the colony purification region for the CLS1/CAF co-culture system with square shapes. (II) Imaging of the entire well after laser-processing. Scale bar, 30mm. The purified areas follow the set laser-shooting pattern. CLS1 colony images of the same view before (III) and after (IV) LEAP processing. (V) Image of a purified CLS1 colony cells after washing the cells with PBS. Scale bar, 5mm.
2 Supplementary Figure 2. The primary culture of lung cancer stem cells and CAFs from NSCLC patients. (a) Tumorous sphere-forming CSCs cultured with CAF feeder cells derived from primary tumor tissues resected from different lung cancer patients (PT207, 013, 270, 450, 220, and 290). The patient demographics, tumor stage, and pathological diagnosis are listed as Supplementary Table 2. Scale bar, 100 m. (b) DNA aneuploidy analysis of CLS1 cells. (c) Flow cytometric analysis of fibroblast surface markers defined the phenotype of CAF feeder cells. The CAFs were positive stained with human fibroblast-specific CD90, HLA-A, -B, and -C (class I), and myofibroblast-specific alpha-sma.
3 Supplementary Figure 3. CAFs co-culture system could be a platform for maintaining lung cancer stemness. (a) Lung CSCs (CLS1) co-cultured with CAFs for 10 days formed similar morphology tumorous spheres in different time point (upper). Scale bar, 50 m. RT Q-PCR analysis of the stem cell markers Nanog and Oct3/4 in CLS1 cells co-cultured with CAFs (CLS1/CAF) in different passages (CLS1/CAF p.3, CLS1/CAF p.6, and CLS1/CAF p.16) (lower), comparing to CAFs and differentiated CLS1 cells.(n=3) (b) The incidence of mouse xenograft tumors from CLS1/CAF co-cultures in different passage (CLS1/CAF p.3, CLS1/CAF p.12, and CLS1/CAF p.16) (N=4-6 mice) in different cell numbers (5 10 6, , , , , and cells) injected subcutaneously into SCID mice. Data represent the mean ±S.D. and tested for significance by Student s t-test *P<0.05. Data are representative of three independent biological experiments each.
4 Supplementary Figure 4. Lung CSCs can maintain stemness ability in vivo. (a) The morphology of tumorous sphere of tumor cells isolated from subcutaneous tumor (SC1-4) and spontaneous lung metastasis (meta-lung) nodules of CLS1/CAF xenograft tumors. Scale bar, 100 m. (b) The incidence of mouse xenograft tumors with sub-cultured CLS1 cells isolated from a CLS1/CAF-derived subcutaneous xenograft (SC-xenograft) (N=4 or 5 mice) and lung metastasis tumor (N=4 or 5 mice). Different numbers of cells (1 10 4, , and cells) were subcutaneously injected into the SCID mice.
5 Supplementary Figure 5. The characterization of lung cancer stem cells under co-culturing with CAFs. (a) The tumorous ultra-low sphere-forming assay showing the morphology of the tumorous spheres of cancer cells/cafs and differentiated cancer cells in different primary lung cancer cell lines (CLS1, CL141, and CL152) seeded in ultra-low adherent plates in MCDB201 medium with EGF (20 ng/ml) and bfgf (20 ng/ml) for 21 days (upper panel). The sphere numbers (N=6) and sphere area (N=10) were quantified (lower panel). Scale bar, 100 m. (b) The ALDH activity of the primary lung cancer cell lines (CLS1, CL141 and CL152) cultured with or without CAFs. The ALDH activity was stained with the ALDEFLUOR dye in the absence (upper) or presence (lower) of DEAB (an ALDH inhibitor) for 30 mins at 37 and analyzed by flow cytometry. (c-d) Side-population analysis of cancer cells in lung cancer cell lines (CLS1-5, A549, H522, H23, Hop62, H322M, and EKVX) and CLS1 cells cultured with or without CAF. Cells were stained with the Hoechst dye (5 g/ml) in the absence (left) or presence (right) of 50 M reserpine for 2 h at 37 and then analyzed by flow cytometry. Data represent the mean ±S.D. and tested for significance by Student s t-test *P<0.05. Data are representative of at least three independent biological experiments each.
6 Supplementary Figure 6. Lung CSCs differentiated into different types of cancer cells in vitro and in vivo. (a) Immunofluorescence staining with different cancer subtype markers, including transcription thyroid factor 1 (TTF-1), cytokeratin-7 (CK7), and cytokeratin-20 (CK20) (for lung adenocarcinoma) or p63 and keratin-5/6 (for squamous cell carcinoma) in different clones of tumor cells (C1, C2, C3, and C4). Scale bar, 20 m. (b) Immunohistochemistry of TTF-1, CK7, CK7, p63, keratin-5/6, and mucin-1 in xenograft tumors (subcutaneous and spontaneous lung metastatic tumors) derived from injection of CLS1 cells co-cultured with CAF feeder cells. A549 cells served as a control. Scale bar, 50 m.
7 Supplementary Figure 7. Different clones of differentiated CLS1 can de-differentiate through re-co-culturing with CAFs. (a) Immunofluorescence staining with different cancer subtype markers, including transcription thyroid factor 1 (TTF-1), cytokeratin-7 (CK7), and cytokeratin-20 (CK20) (for lung adenocarcinoma) or p63 and keratin-5/6 (for squamous cell carcinoma) in different clones of tumor cells (C1, C2, C3, and C4) co-cultured with CAFs (CLS1/CAF). Scale bar, 20 m. (b) RT Q-PCR analysis of the stem cell markers Nanog and Oct3/4 in different clones of tumor cells (C1, C2, C3, and C4) co-cultured with CAFs (CLS1/CAF), comparing to different clones of tumor cells. (N=3) Data represent the mean ±S.D. and tested for significance by Student s t-test *P<0.05. Data are representative of at least three independent biological experiments each. Scale bar, 50 m.
8 Supplementary Figure 8. Full genome Gene expression profiling reveals key signaling pathway in CSCs. (a) Hierarchical clustering of differentially expressed genes in CLS1 cultured with and without CAF feeder cells. Metacore pathway analysis showed up-regulation of genes involved in the EMT, PI3K, IGF1R, TGF-beta, WNT, and Hedgehog signaling pathways in CLS1/CAF co-cultures. (b) Signaling pathway networks that regulate cancer stemness in lung CSCs (Green line means activated, red line as inactivated and pink indicates unspecified). (c) Real-time RT Q-PCR analysis of TGF beta-related pathway molecules (TGFBR1 and SMAD2), a Wnt-related pathway molecule (TCF21), a EGFR-related pathway molecule (EGR1), and LIF-related pathway molecules (LIF and LIFR) in the CLS1/CAF co-culture for 10 days and after serial passages (p3 and p14) of CLS1 cells cultured in the absence of CAFs. Data represent the mean ±S.D. and tested for significance by Student s t-test *P<0.05. Data are representative of three independent biological experiments each.
9 Supplementary Figure 9. Potential paracrine interactions between CAFs and CLS1 cells validated by real-time RT Q-PCR. Candidate genes involved in paracrine cross-talk between CAFs and CSCs (CLS1), including IGF2R, IGFBP1, IGFBP2, IGFBP5, SPARC, decorin, and thromobospondin-1, were validated by Q-PCR. The CLS1 cells (after passage p3, p6, and p14) were derived from CLS1 spheres dissociated to single cells and then sub-cultured without CAFs. The CAFs served as the feeder cell control. Data represent the mean ±S.D. and tested for significance by Student s t-test *P<0.05. Data are representative of three independent biological experiments each.
10 Supplementary Figure10. Reciprocal interaction of genes induced in CAFs by co-culture with lung carcinoma cells. RT Q-PCR analysis of HGF and SDF1 in different patient s CAFs (N=5 patients) cultured with or without A549, EKVX and CLS1 cells. Data represent the mean ±S.D. and tested for significance by Student s t-test *P<0.05. Data are representative of at least three independent biological experiments each.
11 Supplementary Figure 11. The procedures of identifying cancer stem cell through high content analysis. (a) CD90 as the CAF marker; Nanog for the stemness cells; DAPI staining for the nuclei and helpful for identifying the CSC colony by image-based high content analysis. Colony numbers, area, cells per colony, and Nanog-postive cells. Scale bar, 2mm. (b) Image-based high content analysis showing the Nanog (+) colony-forming ability of CLS1 cells increased under the treatment of IGF-II (10 and 100 ng/ml). Data represent the mean ±S.D. and tested for significance by Student s t-test *P<0.05. Data are representative of three independent biological experiments each. Scale bar, 2mm.
12 Supplementary Figure 12. IGF-II induced stemness in different lung cancer cell lines. (a) Flow cytometric analysis with ALDEFLUOR assay of CLS1/CAFs cells treated with IGF-II (100 ng/ml). The fluorescence intensity corresponding to the ALDH activity was measured without DEAB (upper panel) and with DEAB (lower panel). (b) The ALDH activity was examined by flow cytometry in four different lung cancer cell lines (CLS1/CAFs, A549, H1975, and EKVX) treated with IGF-II (100 ng/ml). Data represent the mean ±S.D. and tested for significance by Student s t-test *P<0.05. Data are representative of three independent biological experiments each.
13 Supplementary Figure 13. Blockage of IGF1R signaling by PI3K inhibitor suppresses lung cancer stemness in vitro. (a) The Nanog-positive stem cells per colony were analyzed by image-based high content analysis. The different primary lung cancer cell lines (CLS1, CL141 and CL152) were co-cultured with CAFs treated with or without the PI3K inhibitor (LY under 1, 5 10 M/ml).(N=3) (b) Western blot analysis of Nanog in CLS1 cells treated with IGF-II (10 ng/ml) or IGF-II (10 ng/ml) in combination with PI3K inhibitor (LY294002, 5 M/ml) for 24 h. (c) The tumorigenesis ability of xenograft tumors from CLS1/CAF cells was reduced by treatment with LY The tumors were generated by the injection of 1,000 CLS1/CAF cells. The tumor weight of the CLS1/CAF cells was decreased by the LY (5 M/ml) treatment (N=5 mice each group). Data represent the mean ±S.D. and tested for significance by Student s t-test *P<0.05. Data are representative of three independent biological experiments each.
14 Supplementary Figure 14. Blockage of IGF1R signaling by IGF1R neutralize Ab or inhibitor suppresses stemness in different lung cancer cell lines. (a) The A549, and EKVX cells were co-cultured with CAFs treated with or without IGF1R Ab (1 g/ml); the number of Nanog-positive stem cells per colony was examined. (N=3) Scale bar, 100 m. (b) The Nanog-positive stem cells per colony were analyzed by image-based high content analysis. The different primary lung cancer cell lines (CLS1, CL141 and CL152) were co-cultured with CAFs treated with or without the IGF1R kinase inhibitor (AEW541 under 1, 5 10 M/ml). (N=3) (c) The sphere-forming morphology and ability (Numbers of sphere,n=6; Average area of sphere, N=10) of the lung cancer cell lines, including A549 and EKVX, were significantly reduced by treatment with IGF1R Ab (1 g/ml). Data represent the mean ±S.D. and tested for significance by Student s t-test *P<0.05. Data are representative of at least three independent biological experiments each. Scale bar, 200 m.
15 Supplementary Figure 15. Blockage of IGF1R signaling by IGF1R kinase inhibitors suppresses lung cancer stemness in vivo. The tumorigenesis ability of xenograft tumors from CLS1/CAF cells was reduced by treatment with AEW541. The tumors were generated by the injection of 1,000 CLS1/CAF cells. The tumor weight of the CLS1/CAF cells was decreased by the AEW541 (5 M/ml) treatment (N=5 mice each group).
16 Supplementary Figure 16. Full-scan images of representative Western blots.
17 Supplementary Figure 16. Continued
18 Supplementary Figure 16. Continued
19 Supplementary Figure 16. Continued
20 Supplementary Table 1. Patient demographics, tumor stage, pathological diagnosis Patients Age Sex TNM Stage Histology Primary cultured Cell PT F T1bN0 Stage IA ADC Cancer cell and CAFs PT M T4N Stage IV ADC Cancer cell and CAFs PT M T3N3M1b Stage IV SCLC Cancer cell and CAFs PT M T3N3M1a Stage IV ADC Cancer cell and CAFs PT M T2bN0 Stage IIA ADC CAFs and NFs PT M T3N0 Stage IIB SCC Cancer cell and CAFs PT F T2aN0 Stage IB ADC CAFs and NFs PT M T4N0 Stage IIIB SCC CAFs and NFs PT M T4N3M1b Stage IV ADC Cancer cell and CAFs PT F T2aN0 Stage IIA ADC CAFs and NFs PT M T3N0 Stage IIB SCC CAFs and NFs CLS1 87 M T2bN0 Stage IIIA ASC Cancer cell and CAFs ASC: Adenosquamous carcinoma; ADC: Adenocarcinoma; SCC: Squamous cell carcinoma; SCLC: Small cell lung cancer.
21 Supplementary Table 2. The Metastasis Incidence of CLS1/CAFs, CLS1 and A549 cells Cells Lung metastasis/ mice CLS1/CAFs 12/15 CLS1 2/10 A549 0/3
22 Supplementary Table 3. The IC 50 of CLS1/CAF and CLS1 treated with chemotherapeutic compounds. Drugs IC 50 CLS1/CAF CLS1 Etoposide (VP-16 ) M 1.06 M Docetaxel 54.8 nm 4.2 nm Vinorelbine ditartrate nm 28.5 nm Cisplatin 0.31 M 0.20 M
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
Supplementary Figure 1. HOPX is hypermethylated in NPC. (a) Methylation levels of HOPX in Normal (n = 24) and NPC (n = 24) tissues from the genome-wide methylation microarray data. Mean ± s.d.; Student
A +DEAB -DEAB K ALDEFLUOR-positive/ CXCR-negative BAAA BAAA CXCR-APC B +DEAB -DEAB K ALDEFLUOR-positive/ CXCR-positive BAAA BAAA CXCR-APC C Supplemental Figure. Tumorigenicity of the ALDEFLUOR-positive/CXCR-positive
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell and patient-derived tumor organoids Ling Huang 1, Audrey Holtzinger 1,2,11, Ishaan Jagan 1,11, Michael BeGora 1, Ines
Novel Compound GZ17-06.02 suppresses pancreatic cancer tumorigenesis and metastasis by inhibiting cancer stem cells Animesh Dhar, Ph.D Cancer Biology The University of Kansas Medical Center firstname.lastname@example.org
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
Application Note The Avatar System TM Yields Biologically Relevant Results Liquid biopsies stand to revolutionize the cancer field, enabling early detection and noninvasive monitoring of tumors. In the
ΕΛΙΞΕΙΣ ΣΤΗΝ ΑΝΟΣΟΘΕΡΑΠΕΙ ΤΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ Δημήτρης Μαυρουδής Παθολόγος - Ογκολόγος Πανεπιστημιακό Νοσοκομείο Ηρακλείου LUNG CANCER INCIDENCE LUNG CANCER MORTALITY LUNG CANCER Non-small Cell Lung
www.sciencesignaling.org/cgi/content/full/9/418/ra27/dc1 Supplementary Materials for The adhesion molecule PECAM-1 enhances the TGF- mediated inhibition of T cell function Debra K. Newman,* Guoping Fu,
1 Our speaker for this program is Dr. Anja Roden, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic as well as consultant in the Anatomic Pathology Laboratory and co-director of
Supplementary Figure 1. mrna expression of chitinase and chitinase-like protein in splenic immune cells. Each splenic immune cell population was sorted by FACS. Surface markers for sorting were CD11c +
Supplementary material Supplementary Figure legends Supplementary Figure 1: Senescence-associated proliferation stop in response to oncogenic N-RAS expression Proliferation of NHEM cells without (ctrl.)
Final report ESMO Translational Research Fellowship 2010-2011 Molecular and genetic analysis of stromal fibroblasts in prostate cancer Michalis Karamouzis Host Institute Department of Biological Chemistry,
Supplementary Table 1. List of primers used in this study Gene Forward primer Reverse primer Rat Met 5 -aggtcgcttcatgcaggt-3 5 -tccggagacacaggatgg-3 Rat Runx1 5 -cctccttgaaccactccact-3 5 -ctggatctgcctggcatc-3
Silva et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability Supplementary Table; Supplementary Figures and legends S1-S21; Supplementary
Stat3 Transgenic Mice as a Model for Human Basal Subtype of Invasive Bladder Cancer Philip L. Ho, MD Urologic Oncology Fellow The University of Texas at MD Anderson Cancer Center Houston, TX None Disclosures
Supplementary Figure 1 RNA-Seq analysis of CD8 + TILs and N-TILs. (a) Schematic representation of the tumor and cell types used for the study. HNSCC, head and neck squamous cell cancer; NSCLC, non-small
Research article Human ovarian carcinoma associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production Karen McLean, 1 Yusong Gong, 2 Yunjung Choi, 2 Ning Deng,
mir-509-5p and mir-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer Hidekazu Hiramoto, M.D. 1,3, Tomoki Muramatsu, Ph.D. 1, Daisuke Ichikawa,
Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch
Cancer Medicine ORIGINAL RESEARCH Open Access Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma Zhengbo Song 1,2, Xinmin Yu 1 & Yiping Zhang 1,2 1 Department
Carcinoma of the Lung: A Really Dismal Histologic Variant? Dae Joon Kim, MD, Kil Dong Kim, MD, Dong Hwan Shin, MD, Jae Y Ro, MD, and Kyung Young Chung, MD Departments of Thoracic and Cardiovascular Surgery,
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 287, NO. 51, pp. 42502 42515, December 14, 2012 2012 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A. Artemin Stimulates
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
Cytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics Mercè Jordà, University of Miami Mortality Lung cancer is the most frequent cause of cancer incidence and mortality
Supplementary Information Supplementary Fig. 1. Elevated Usp9x in melanoma and NRAS mutant melanoma cells are dependent on NRAS for 3D growth. a. Immunoblot for Usp9x protein in NRAS mutant melanoma cells
Guideline for the Handling of Pathology Lung Tissue Specimens Version Date Summary of Change/Process 0.1 29.06.11 Produced by Simon Trotter and circulated to Lung Network Site Specific Group for reviewing
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
The new role of cytology in the diagnosis and management of lung cancer Maureen F. Zakowski, M.D. Memorial Sloan-Kettering Cancer Center Outline Role of cytology in the diagnosis of lung cancer Non-small
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure 1. Fbn1 C1039G/+ hearts display normal cardiac function in the absence of hemodynamic stress. A. Echocardiographic quantification of cardiac dimensions and
MOLECULAR CARCINOGENESIS Sonic Hedgehog (Shh) Signaling Promotes Tumorigenicity and Stemness via Activation of Epithelial-to-Mesenchymal Transition (EMT) in Bladder Cancer S.S. Islam, 1,2 R.B. Mokhtari,
Characteristics of lung cancers detected in the randomized NELSON lung cancer screening trial Nanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen,
Ets-1 identifying polynucleotide sequence for targeted delivery of anti-cancer drugs Indian Patent Application No. 1623/DEL/2014 Inventors: Prof. Kulbhushan Tikoo and Jasmine Kaur Department of Pharmacology
Epithelial Mesenchymal Transition (EMT) and CTCs Massimo Cristofanilli, M.D., F.A.C.P. Professor of Medical Oncology Deputy Director of Translational Research Director of the Jefferson Breast Cancer Center
AD Award Number: W81XWH-08-1-0306 TITLE: Characterizing an EMT Signature in Breast Cancer PRINCIPAL INVESTIGATOR: Melanie C. Bocanegra CONTRACTING ORGANIZATION: Leland Stanford Junior University Stanford,
Steering Committee Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD MD, PhD Waiting on photo Paul Van Schil, MD, PhD William D. Travis, MD Ming-Sound Tsao,
Author's response to reviews Title:microRNA alterations in mammary epithelial stem cells: a crucial contributing factor towards breast cancer risk reduction in case of early pregnancy Authors: Sushmita
Supplementary Materials: Supplementary Figure 1. IDH1 and IDH2 mutation site sequences on WHO grade III patient samples. Genomic DNA samples extracted from punch biopsies from either FFPE or frozen tumor
Supplementary Figure 1: Expression of NFAT proteins in Nfat2-deleted B cells (a+b) Protein expression of NFAT2 (a) and NFAT1 (b) in isolated splenic B cells from WT Nfat2 +/+, TCL1 Nfat2 +/+ and TCL1 Nfat2
Anatomic Pathology / Lung Carcinoma Classification Usefulness of Immunohistochemical and Histochemical Studies in the Classification of Lung Adenocarcinoma and Squamous Cell Carcinoma in Cytologic Specimens
Pr John DE VOS Département d Ingénierie Cellulaire et Tissulaire INSERM 1183 - IRMB Hôpital St Eloi - CHU de Montpellier email@example.com @_jdevos_ TUMOR INITIATING CELLS: THE STEM CELL THEORY OF CANCER
Biomedical Research 2017; 28 (14): ISSN 0970-938X www.biomedres.info Study of the relationship between EGFR mutation status and bone metastasis in advanced lung adenocarcinoma. Xiaoye Ai, Adalati Yasheng,
Research article Hunk is required for HER2/neu-induced mammary tumorigenesis Elizabeth S. Yeh, 1 Thomas W. Yang, 1 Jason J. Jung, 1 Heather P. Gardner, 1 Robert D. Cardiff, 2 and Lewis A. Chodosh 1 1 Department
Supplementary Figure 1. mrna targets were found in exosomes and absent in free-floating supernatant. Serum exosomes and exosome-free supernatant were separated via ultracentrifugation and lysed to analyze
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
ORIGINAL ARTICLE Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and III-Tubulin Between Primary Non-small Cell Lung Cancer
Liquid Biopsy Jesus Garcia-Foncillas MD PhD Director Main issues about liquid biopsies New paradigm: Precision Medicine Heterogeneity & Dynamics Surrogate mirror for the tumor CTCs in colon cancer ctdna:
Extended Neurosphere Culture of Brain Tumor Stem Cells with the PromoCell 3D Tumorsphere Medium XF Application Note The PromoCell 3D Tumorsphere Medium XF While adherent cultures of brain tumor cells in
Small Molecule Inhibitor of the Wnt Pathway (SM755) as a Potential Topical Scleroderma Treatment Vishal Deshmukh, PhD, Allison Hood, Yusuf Yazici, MD Disclosures Vishal Deshmukh, Ph.D. o Financial disclosure:
TGFβ/BMP/Smad signaling pathway Dr. Jean Jacques Lebrun Professor of Medicine, McGill University Health Center, Cancer Research Program Associate Dean, Graduate & Postdoctoral Studies McGill University
CASE REPORT Primary enteric adenocarcinoma with predominantly signet ring features of the lung: A case report with clinicopathological and molecular findings Makoto Nagashima 1, Ayako Moriyama 1, Yasuo
PI3K Background The phosphatidylinositol 3-kinase (PI3K) pathway is a key cell signaling node whose dysregulation commonly results in the transformation of normal cells into cancer cells. The role of PI3K
The role of growth factors in regulating cellular events during ovarian follicular development Leon J. Spicer Department of Animal Science, Oklahoma State University, Stillwater, OK USA SESSION #54 EAAP
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
Supplementary Fig. S1. Evaluation of the purity and maturation of macrophage cultures tested by flow cytometry. The lymphocytic/monocytic cellular fraction was isolated from buffy coats of healthy donors
Cell Stem Cell, Volume 20 Supplemental Information Induction of Expansion and Folding in Human Cerebral Organoids Yun Li, Julien Muffat, Attya Omer, Irene Bosch, Madeline A. Lancaster, Mriganka Sur, Lee
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
Supplementary Figure 1 a Percent of body weight! (%) 4! 3! 1! Epididymal fat Subcutaneous fat Liver SD Percent of body weight! (%) ** 3! 1! SD Percent of body weight! (%) 6! 4! SD ** b Blood glucose (mg/dl)!
Related Commentary, page 2528 Research article Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelialmesenchymal transition Erica L. McCoy,
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
Supplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk -/- mice were stained for expression of CD4 and CD8.
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Large cell neuroendocrine carcinoma: retrospective analysis of 24 cases from four oncology centers in Turkey Bala Başak Oven Ustaalioglu 1, Arife Ulas 2,
Squamous cell carcinoma lung icd 10 The Borg System is 100 % Squamous cell carcinoma lung icd 10 ICD-10: C34.90 Short Description: Malignant neoplasm of unsp part of unsp bronchus or lung Long Description:.
Supplementary Figure 1 Expression of apoptosis-related genes in tumor T reg cells. (a) Identification of FOXP3 T reg cells by FACS. CD45 + cells were gated as enriched lymphoid cell populations with low-granularity.
S5.01 The tumour stage and stage grouping must be recorded to the extent possible, based on the AJCC Cancer Staging Manual (7 th Edition). 11 (See Tables S5.01a and S5.01b below.) Table S5.01a AJCC breast
Cancer Cell, Volume 7 Supplemental Information Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate Bin Zhang,
Supplemental materials 1 Supplemental Fig. 1 Immunogram This immunogram summarizes patient clinical data and immune parameters at corresponding time points for Patient IMF-32. The top panel illustrates
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference: